rinatabart sesutecan + bevacizumab

**Rinatabart sesutecan + bevacizumab** is an investigational **combination therapy** comprised of rinatabart sesutecan (Rina-S), a folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC), and bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). Rinatabart sesutecan consists of a human monoclonal antibody targeting FRα, a hydrophilic protease-cleavable linker, and exatecan (a topoisomerase I (TOPO1) inhibitor) as the cytotoxic payload[1]. Bevacizumab inhibits angiogenesis by neutralizing VEGF-A. This combination is being tested in advanced solid tumors—particularly endometrial and ovarian cancer{1}.

Other names

rinatabart sesutecanRina-SGEN1184GEN-1184GEN 1184PRO1184PRO-1184PRO 1184bevacizumabAvastin